Get the latest market trends in your inbox
Stay on top of the latest market trends and economic insights with the Axios Markets newsletter. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Denver news in your inbox
Catch up on the most important stories affecting your hometown with Axios Denver
Des Moines news in your inbox
Catch up on the most important stories affecting your hometown with Axios Des Moines
Minneapolis-St. Paul news in your inbox
Catch up on the most important stories affecting your hometown with Axios Minneapolis-St. Paul
Tampa-St. Petersburg news in your inbox
Catch up on the most important stories affecting your hometown with Axios Tampa-St. Petersburg
Photo: Tim Boyle/Getty Images
The Trump administration is moving ahead with a proposal that would require drug companies to include the sticker prices of their products in direct-to-consumer advertising — a controversial part of President Trump's blueprint for lower drug prices.
Between the lines: As simple and straightforward as price disclosures might sound, this information may not end up being very useful. Few patients pay the sticker price for a drug. Their insurance plans negotiate discounts, and then often pay only a fraction of that amount.
Driving the news: The White House budget office is reviewing a proposed rule on "drug price transparency."
- Two sources familiar with the proposal said it would implement Trump's call to require pricing information in consumer-focused advertising. One of those sources said it would be drugs' list prices.
What to watch: This will be controversial. Drugs' list prices are much higher than the prices most consumers actually pay. But because every insurance plan is different, it's hard to find a single alternative that would give patients a more accurate picture of their own price tag.